By: Rahul Koul
Last updated : April 07, 2026 1:32 pm
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The rapid rise of Semaglutide from a niche diabetes therapy to a widely discussed weight-loss solution marks one of the most striking shifts in India’s pharmaceutical landscape.
Originally developed to treat Type 2 Diabetes, the drug is now at the center of a demand surge driven by its effectiveness in managing Obesity, a condition that has long lacked safe and scalable medical interventions.
Marketed globally under brands such as Ozempic and Wegovy by Novo Nordisk, semaglutide has demonstrated significant weight reduction alongside improved glycaemic control and cardiovascular outcomes. Its mechanism, mimicking the GLP-1 hormone that regulates appetite, has helped reframe obesity as a biological condition, expanding both physician acceptance and patient demand.
That demand is now translating into a full-scale market shift in India following the expiry of semaglutide’s patent in March 2026. The patent cliff has triggered an unprecedented rush among domestic drugmakers to launch affordable generics, fundamentally altering the accessibility and pricing dynamics of this once-premium therapy.
The sudden market boom
As per reports, the anti-obesity drug market touched Rs 1,230 crore in 2025, up 115% year-on-year, driven largely by semaglutide and tirzepatide adoption. Before generic entry, semaglutide therapies such as Ozempic/Wegovy were priced at Rs 8,800–16,400 per month, limiting access mainly to affluent urban users.
Among the early movers, Dr. Reddy’s Laboratories has already launched a generic version, while Alkem Laboratoriesand Natco Pharma have introduced competitively priced variants targeting both diabetes and weight-loss segments.
At the same time, partnerships and pipeline plays are intensifying. Zydus Lifesciences and Lupin have entered into a co-marketing agreement for semaglutide injections, while companies such as Sun Pharma, Biocon and MSN Laboratories are preparing their own formulations and delivery systems.
Industry estimates suggest that more than 40 companies could collectively launch over 50 brands of semaglutide in India, triggering intense price competition and potentially reducing therapy costs by as much as 90 percent. This influx is expected to dramatically expand access in a country with one of the world’s largest populations of diabetic and overweight patients.
The commercial opportunity has also drawn global collaborations. Abbott has partnered with Novo Nordisk to expand access to semaglutide through branded offerings in India, highlighting the hybrid model of innovator and generic coexistence in this fast-evolving market.
Regulator steps in
However, the drug’s rapid mainstreaming, fueled in part by social media and celebrity-driven narratives, has raised regulatory concerns.
The Central Drugs Standard Control Organization (CDSCO) has issued an order prohibiting the advertisement of semaglutide and similar prescription drugs to the general public. The directive aims to prevent misleading promotion, particularly around weight-loss claims, and to ensure that such therapies are used strictly under medical supervision.
The regulator’s intervention comes at a time when global experience has already highlighted risks of misuse and supply diversion. In several markets, demand driven by non-diabetic users has led to shortages, impacting patients who rely on the drug for diabetes management. India now faces a similar balancing act between expanding access and ensuring responsible use.
Outlook
India’s semaglutide market is shifting from a Rs 1,000+ crore premium segment to a high-volume affordable mass market after generic entry, making it one of the fastest-growing opportunities in diabetes and obesity care.
Despite its promise, semaglutide is not without limitations. Side effects, the potential for weight regain after discontinuation, and long-term affordability remain key concerns. Moreover, as prices fall and competition intensifies, questions around quality consistency and physician trust are likely to shape market leaders in the months ahead.